definiens: meansenrollment of the first patient in a Phase III clinicaltrial of a Product June 1, 2019 $ 100,000 Successful completion of a Phase III clinical trial of aProduct, where meansreceipt of an approved New Drug Application ( NDA)from the FDA or foreign equivalent for a Product June 1, 2022 $ 150,000 First sale of a Product June 1, 2025 $ 400,000 Page 4 of 12For the purposes of this Section 5.01, a means a therapeutic composition within the LICENSEDPRODUCTS that is selected for entry into clinical trials for a specified indication . Milestone AchievementPayments, according to the above schedule, shall be payable to SYSTEM upon the attainment of the milestonewith respect to each Product . LICENSEE shall provide written notification to SYSTEM within thirty ( 30 ) days ofachieving each milestone